Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNPGet Free Report) in a note issued to investors on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Down 4.5 %

TTNP opened at $6.42 on Friday. The stock’s 50 day moving average price is $6.92 and its two-hundred day moving average price is $6.88. Titan Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $16.59.

Titan Pharmaceuticals (NASDAQ:TTNPGet Free Report) last released its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) earnings per share for the quarter. Titan Pharmaceuticals had a negative net margin of 2,014.71% and a negative return on equity of 99.96%.

About Titan Pharmaceuticals

(Get Free Report)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.

Featured Articles

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.